Business Context and Reporting Period
Mereo Biopharma Group Plc, a clinical-stage UK-based biopharmaceutical company focused on rare diseases, filed this Form 6-K on May 22, 2019. The filing serves as a notification of dealings by a Person Discharging Managerial Responsibilities (PDMR) in accordance with the EU Market Abuse Regulation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial report.
Material Changes and Transaction Details
The filing discloses a specific transaction involving company leadership:
- Person: Alexandra ("Wills") Hughes-Wilson, Head of Patient Access & Commercial Planning.
- Date: May 20, 2019.
- Transaction: Purchase of 1,650 American Depositary Shares (ADSs).
- Price: USD 5.42 per share.
- Exchange: NASDAQ (XNMS).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosure of the PDMR transaction.
Key Facts for Investor Verification
- Verify the current share price relative to the USD 5.42 purchase price by the Head of Patient Access & Commercial Planning.
- Confirm the total number of ADSs held by Alexandra Hughes-Wilson following this purchase to assess insider confidence levels.
- Review recent clinical trial updates or regulatory filings to understand the company's operational progress, as this filing contains no operational data.